172 related articles for article (PubMed ID: 28925879)
1. Human Fibronectin Extra-Domain B (EDB)-Specific Aptide (APTEDB) Radiolabelling with Technetium-99m as a Potent Targeted Tumour-Imaging Agent.
Mohammadgholi M; Sadeghzadeh N; Erfani M; Abediankenari S; Abedi SM; Emrarian I; Jafari N; Behzadi R
Anticancer Agents Med Chem; 2018; 18(2):277-285. PubMed ID: 28925879
[TBL] [Abstract][Full Text] [Related]
2. In vitro/in vivo assessment of the targeting ability of [
Ranjbar L; Maleki F; Sadeghzadeh N; Abediankenari S; Mardanshahi A; Masteri Farahani A
Ann Nucl Med; 2020 Jul; 34(7):460-466. PubMed ID: 32390105
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a New
Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S
J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899
[TBL] [Abstract][Full Text] [Related]
5. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920
[TBL] [Abstract][Full Text] [Related]
7. MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles.
Sun Y; Kim HS; Park J; Li M; Tian L; Choi Y; Choi BI; Jon S; Moon WK
Theranostics; 2014; 4(8):845-57. PubMed ID: 24955145
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging.
Park J; Kim S; Saw PE; Lee IH; Yu MK; Kim M; Lee K; Kim YC; Jeong YY; Jon S
J Control Release; 2012 Oct; 163(2):111-8. PubMed ID: 22964395
[TBL] [Abstract][Full Text] [Related]
9. Lys3-bombesin conjugated to 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging.
Mendoza-Sánchez AN; Ferro-Flores G; Ocampo-García BE; Morales-Avila E; de M Ramírez F; De León-Rodríguez LM; Santos-Cuevas CL; Medina LA; Rojas-Calderón EL; Camacho-López MA
J Biomed Nanotechnol; 2010 Aug; 6(4):375-84. PubMed ID: 21323111
[TBL] [Abstract][Full Text] [Related]
10. Targeted Cancer Therapy Using Fusion Protein of TNFα and Tumor-Associated Fibronectin-Specific Aptide.
Jeon H; Kim D; Choi M; Kang S; Kim JY; Kim S; Jon S
Mol Pharm; 2017 Nov; 14(11):3772-3779. PubMed ID: 28969419
[TBL] [Abstract][Full Text] [Related]
11. New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification.
Emrarian I; Sadeghzadeh N; Abedi SM; Abediankenari S
Chem Biol Drug Des; 2018 Jan; 91(1):304-313. PubMed ID: 28816013
[TBL] [Abstract][Full Text] [Related]
12. Clinical translation of a PSMA inhibitor for
Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
14.
Rezazadeh F; Sadeghzadeh N; Abedi SM; Abediankenari S
Nucl Med Biol; 2018; 62-63():54-62. PubMed ID: 29885559
[TBL] [Abstract][Full Text] [Related]
15. Lys and Arg in UBI: a specific site for a stable Tc-99m complex?
Meléndez-Alafort L; Ramírez Fde M; Ferro-Flores G; Arteaga de Murphy C; Pedraza-López M; Hnatowich DJ
Nucl Med Biol; 2003 Aug; 30(6):605-15. PubMed ID: 12900286
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Assisted Delivery of a Peptide-Drug Conjugate for Targeted Cancer Therapy.
Kim H; Hwang D; Choi M; Lee S; Kang S; Lee Y; Kim S; Chung J; Jon S
Mol Pharm; 2019 Jan; 16(1):165-172. PubMed ID: 30521347
[TBL] [Abstract][Full Text] [Related]
17. 99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand.
Wang J; Kim YS; Liu S
Bioconjug Chem; 2008 Mar; 19(3):634-42. PubMed ID: 18281926
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence.
Decristoforo C; Mather SJ
Eur J Nucl Med; 1999 Aug; 26(8):869-76. PubMed ID: 10436200
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores.
Decristoforo C; Santos I; Pietzsch HJ; Kuenstler JU; Duatti A; Smith CJ; Rey A; Alberto R; Von Guggenberg E; Haubner R
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):33-41. PubMed ID: 17372571
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
